作者
Francisco Javier Martínez-Martín,Sara Andrada-Diaz,Agnieszka Kuzior,Ana Maria Sanchez Garcia,Juan Fernández-Jiménez,Irene Hernandez-Hernandez,Facundo Marcelo Guerrero-Kesselman,Borja Santana-Ojeda,Inmaculada Molinero-Marcos,Claudia Arnas-Leon
摘要
Introduction and Objectives In the adult Spanish population the prevalence of prediabetes has been estimated at 15%, with an annual diabetes incidence of 1.16% (approximately 386 000 individuals). While metformin, glitazones, GLP-1RAs and SGLT2is may reduce this risk, none is currently approved for this indication. Acarbose, an α-glucosidase inhibitor, reduces the risk of progression to T2DM (STOP-NIDDM trial). White mulberry (Morus Alba) leaves contain 1-deoxynojirimycin, a potent α-glucosidase inhibitor. A nutraceutical based on a standardized white mulberry leaf extract, also containing fenugreek, inulin, Lactiplantibacillus plantarum A14, chromium, zinc and niacin has been developed for the treatment of prediabetes. We conducted an open-label trial (NoDiab) to evaluate the tolerability and efficacy of this nutraceutical, using the HOMA2-IR index (a validated predictor of T2DM development) as the primary outcome. Methods Adult subjects with prediabetes were recruited, excluding those with morbid obesity, serious concomitant diseases, alcoholism, substance abuse, and current or planned pregnancy. After informed consent, baseline anthropometry and laboratory tests, they were instructed to take one pill of the nutraceutical daily before lunch with a glass of water. Follow- up visits are scheduled at 3-4 and 6-7 months. In addition to changes in the HOMA2-IR, secondary endpoints were HOMA2-β, 10-year cardiovascular risk (SCORE2), lipid profile, systolic BP, BMI, fasting glucose and insulin, HbA1c, albuminuria, liver fibrosis risk (FIB-4 index) and tolerability (questionnaire). Results In 113 subjects (71 women, age 56.4 ± 6.7 years), HOMA2-IR decreased from 1.659 ± 0.721 to 1.269 ± 0.581 (P < .001) while HOMA2-β remained unchanged; SCORE2 decreased from to 4.23 ± 1.98 to 3.58 ± 1.76% (P < .001); non-HDLc from 161.5 ± 31.2 to 145.1 ± 20.9 mg/dL (P < .001); systolic BP from 138.8 ± 13.6 to 133.1 ± 11.2 mmHg (P < .001); fasting glucose from 107.5 ± 10.8 to 98.5 ± 8.9 mg/dL (P < .001); fasting insulin from 12.6 ± 6.1 to 9.7 ± 4.4 μU/ml (P < .001); HbA1c from 6.06 ± 0.24 to 5.83 ± 0.18% (P < .001); albuminuria from 28.4 ± 15.2 to 21.5 ± 14.3 mg/g Cr (P = .035); C-reactive protein from 3.66 ± 1.97 to 2.89 ± 1.27 mg/dL (P < .001); FIB-4 index from 1.42 ± 0.25 to 1.22 ± 0.24 (P = .003). Weight reduction was non-significant. No serious tolerability issues were reported, and no patient withdrew from the study due to adverse effects. Conclusions In the open-label NoDiab study, this nutraceutical produced a significant reduction in insulin resistance (−22.5%), along with improvements in the cardiovascular risk profile of prediabetic subjects (15.4% reduction in SCORE2, 9.9% in non-HDL cholesterol and 5.7 mmHg in systolic BP), with excellent tolerability. Prediabetes is primarily managed through lifestyle modifications, but their effectiveness is limited and no pharmacological options are currently approved; this nutraceutical may help fill this therapeutic gap.